ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Search by Abstract Number Results

  • Abstract Number: L17 • ACR Convergence 2024

    Allogenic CD19 CAR NK Cells Therapy in Refractory Systemic Lupus Erythematosus: An Open-label, Single Arm, Prospective and Interventional Clinical Trial

    Yiyi Yu1, Ruina Kong1, Xia Xu1, Suxuan Liu1, Qian Chen1, Xiaofang Li2, Ming Sun2, Jianmin Yang1, Dongbao Zhao1 and Jie Gao1, 1Changhai Hospital, Shanghai, China, 2Rui Therapeutics, Nanjing, China

    Background/Purpose: Treatment of systemic lupus erythematosus (SLE) typically necessitates long-term immunosuppression with hormones, immunosuppressants and biologics. CD19-targeting chimeric antigen receptor (CAR) T cells have shown excellent…
  • Abstract Number: L17 • ACR Convergence 2023

    Safety, Tolerability, and Exploratory Efficacy of Afimetoran, a TLR7/8 Inhibitor, in Patients with Cutaneous Lupus Erythematosus: A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study

    Fareeda Hosein1, Stanislav Ignatenko2, Kristina Chadwick1, Lin Zhu1, Frédéric Baribaud1, Thanh Bach1, Hazem Karabeber1, Michelle Dawes1, Leon Carayannopoulos1 and Gopal Krishna1, 1Bristol Myers Squibb, Princeton, NJ, 2Charité Research Organisation GmbH, Berlin, Germany

    Background/Purpose: Over 50 years have passed since the last therapy was approved for cutaneous lupus erythematosus (CLE).1 Parenteral administration, off-label use, or toxicity with long-term…
  • Abstract Number: L17 • ACR Convergence 2022

    Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis

    Robert Maughan1, Andrew Porter1, Chanaka Dahanayake2, Claudia Ianonne1, Ritu Alapat1, Charis Pericleous1, Taryn Youngstein3 and Justin Mason1, 1Imperial College London, London, United Kingdom, 2Barts Health NHS Trust, London, United Kingdom, 3Imperial NHS Trust, London, United Kingdom

    Background/Purpose: Immunosuppression in Takayasu Arteritis (TA) reduces the risk of arterial damage and disease progression. However, long-term use of glucocorticoids (GC) and other immunosuppressants carries…
  • Abstract Number: L17 • ACR Convergence 2021

    Additional Heterologous versus Homologous Booster Vaccination in Immunosuppressed Patients Without SARS-CoV-2 Antibody Seroconversion After Primary mRNA Vaccination: A Randomized Controlled Trial

    Michael Bonelli1, Daniel Mrak1, Selma Tobudic1, Daniela sieghart1, Peter Mandl1, barbara kornek1, elisabeth simader1, Maximilian Koblischke1, Helga Radner1, thomas perkmann1, helmuth haslacher1, Margareta Mayer1, philipp hofer1, Kurt Redlich2, Emma Husar-Memmer3, Ruth Fritsch-Stork4, Renate Thalhammer1, Karin Stiasny1, Stefan Winkler1, Josef Smolen1, Judith Aberle1, Markus Zeitlinger1, Leonhard Heinz1 and Daniel Aletaha5, 1Medical University of Vienna, Vienna, Austria, 2Hietzing Hospital, Vienna, Austria, 3Hanusch Hospital, Vienna, Austria, 4Sigmund Freud University, Utrecht, Netherlands, 5Medical University Vienna, Wien, Austria

    Background/Purpose: Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)-induced coronavirus disease 2019 (COVID-19) has led to exponentially rising mortality, particularly in immunosuppressed patients, who inadequately respond to…
  • Abstract Number: L17 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial

    Eric Morand1, Richard Furie 2, Yoshiya Tanaka 3, Ian Bruce 4, Anca Askanase 5, Christophe Richez 6, Sang-Cheol Bae 7, Philip Brohawn 8, Lilia Pineda 9, Anna Berglind 10 and Raj Tummala 9, 1Monash University, Melbourne, Victoria, Australia, 2Zucker School of Medicine at Hofstra/Northwell, New York, 3University of Occupational and Environmental Health, Kitakyushu, Japan, 4University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, 5Columbia University, New York, 6CHU de Bordeaux-GH Pellegrin, Bordeaux, France, 7Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 8Former employee of AstraZeneca, Gaithersburg, Maryland, 9AstraZeneca, Gaithersburg, Maryland, 10AstraZeneca, Gothenburg, Sweden

    Background/Purpose: Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2 study in patients with…
  • Abstract Number: L17 • 2018 ACR/ARHP Annual Meeting

    Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study

    Christopher T. Ritchlin1, Arthur Kavanaugh2, Joseph F. Merola3, Georg Schett4, Jose U. Scher5, Richard B. Warren6, Deepak Assudani7, Thomas Kumke8, Barbara Ink7 and Iain B. McInnes9, 1University of Rochester Medical Centre, Rochester, NY, 2UC San Diego School of Medicine, La Jolla, CA, 3Brigham and Women's Hospital Harvard Medical School, Boston, MA, 4Friedrich Alexander University Erlangen-Nurnberg, Erlangen, Germany, 5Department of Medicine, NYU Langone Medical Center, New York, NY, 6The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom, 7UCB Pharma, Slough, United Kingdom, 8UCB Pharma, Monheim am Rhein, Germany, 9University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: IL-17F shares structural homology and overlapping biologic function with IL-17A. In vitro studies demonstrate that IL-17F has biologic effector function that can modulate inflammation.…
  • Abstract Number: L17 • 2014 ACR/ARHP Annual Meeting

    Bariatric Surgery Improves Rheumatoid Arthritis Disease Activity, Reduces Inflammatory Markers, and Decreases Medication Usage

    Jeffrey A. Sparks1, Florencia Halperin2, Jonathan C. Karlson3, Elizabeth W. Karlson1 and Bonnie L. Bermas1, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Obesity causes a chronic inflammatory state. Increased body mass index (BMI) is associated with incident rheumatoid arthritis (RA) and may impact RA disease activity.…
  • Abstract Number: L17 • 2013 ACR/ARHP Annual Meeting

    Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults with Autoimmune Disease

    Lawrence McAdam1, Michael Eberhardson2, William Grainger3, Kim Papp4, Stephen Hall5, Tina Sterling6, Jon Stek6, Lei Pang6, Yanli Zhao6, Ivan Chan6, Richard Haupt6, Janie Parrino6 and Jeffrey Silber6, 1Advanced Rheumatology, Infusion and Clinical Research Center, Thousand Oaks, CA, 2Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 3Neurological Physicians of Arizona, Gilbert, AZ, 4K. Papp Clinical Research,, Waterloo, ON, Canada, 5Emeritus Research, Malvern, Australia, 6Merck & Co., Inc., Whitehouse Station, NJ

    Background/Purpose: Patients with autoimmune diseases are often immunocompromised, resulting in higher incidence of HZ than in immunocompetent individuals with significant morbidity and occasional mortality from…
Search Again »

Didn't find what you were looking for? Try the Advanced Search »

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology